25 Jul 2017 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Senior Management Appointment
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Dr. Christian Bernard Milla, aged 55, as Chief Operating Officer ('COO'), a Board appointment, with effect from 16th August 2017.
At the same time Gracielle Schutjens, formely Chief Operations Officer, will step down from the Board and assume a new role of Business Development Director.
Christian is an experienced COO with a successful record of delivering operational excellence in growing Clinical Research Organisations, as well as driving revenue generation and business growth.
Christian joins Venn from Oncodesign Biotechnology, a leader in preclinical evaluations for anticancer, based in France, where he was Chief Operating Officer. He was also a Board member of Cromsource, a provider of outsourced services to the pharmaceutical, biotechnology and medical device industries. From 2004 until 2007 Christian was CEO of OSMO Accovion SA, a niche Oncology Site Management and CRO. Prior to this he held roles with Parexel, Staticon International and Abbott Laboratories.
Christian will operate from the Venn offices in Paris. He is a French citizen and has a PhD in Neurosiences from the University of Paris.
A list of directorships, both current and in the past five years is included below. Christian does not currently own any Venn shares and confirms that there are no other items requiring disclosure in accordance with Schedule 2(G)(iii) to (Viii) of the AIM Rules and the ESM Rules.
Tony Richardson, Chief Executive Officer of Venn said: "I'm delighted that Christian is joining our team at Venn and we're confident that his operational expertise will ensure that we build on the momentum created in 2016 whilst driving further growth both organically and through acquisition going forward.
"Gracielle has made a considerable contribution to our organisation combining both her COO activities with those of business development. Given her successful delivery of significant new business to the Company to date, we are confident that a singular focus on the Business Development side of her role will pay dividends for Venn."
Current Directorships Milla Projects Consulting SARL | Directorships in the last five years PhenoPups SAS Cromsource Milla Projects Consulting SARL |
Enquiries:
Venn Life Sciences Holdings Plc |
| ||
Allan Wood, Non-Executive Chairman | Tel: +44(0)7785325898 | ||
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | ||
|
| ||
Davy (Nominated Adviser, ESM Adviser and Joint Broker) |
| ||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | ||
|
| ||
|
| ||
Hybridan LLP (Co-Broker) |
| ||
Claire Louise Noyce | Tel: +44(0) 20 3764 2341 | ||
|
| ||
Walbrook PR Ltd | Tel: +44(0)20 7933 8787 or venn@walbrookpr.com | ||
Paul McManus | Mob: +44(0) 7980 541 893 | ||
Lianne Cawthorne | Mob: +44(0) 7584 391 303 | ||
About Venn Life Sciences:
Venn Life Sciences is a European Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in tailored end to end drug development consultancy and clinical trial management services.